- Home
- NBIX vs SNN Comparison
NBIX vs SNN Comparison
Compare NBIX & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- SNN
- Stock Information
- Founded
- NBIX 1992
- SNN 1856
- Country
- NBIX United States
- SNN United Kingdom
- Employees
- NBIX N/A
- SNN N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- SNN Industrial Specialties
- Sector
- NBIX Health Care
- SNN Health Care
- Exchange
- NBIX Nasdaq
- SNN Nasdaq
- Market Cap
- NBIX 12.2B
- SNN 12.6B
- IPO Year
- NBIX 1996
- SNN 1999
- Fundamental
- Price
- NBIX $127.72
- SNN $30.63
- Analyst Decision
- NBIX Strong Buy
- SNN Hold
- Analyst Count
- NBIX 20
- SNN 3
- Target Price
- NBIX $163.20
- SNN $27.50
- AVG Volume (30 Days)
- NBIX 857.9K
- SNN 913.5K
- Earning Date
- NBIX 07-31-2025
- SNN 07-31-2025
- Dividend Yield
- NBIX N/A
- SNN 2.35%
- EPS Growth
- NBIX N/A
- SNN 56.15
- EPS
- NBIX 2.96
- SNN 0.47
- Revenue
- NBIX $2,412,600,000.00
- SNN $5,810,000,000.00
- Revenue This Year
- NBIX $16.29
- SNN $6.87
- Revenue Next Year
- NBIX $15.08
- SNN $5.19
- P/E Ratio
- NBIX $42.60
- SNN $32.39
- Revenue Growth
- NBIX 21.73
- SNN 4.70
- 52 Week Low
- NBIX $84.23
- SNN $23.69
- 52 Week High
- NBIX $157.98
- SNN $31.72
- Technical
- Relative Strength Index (RSI)
- NBIX 61.87
- SNN 61.04
- Support Level
- NBIX $125.02
- SNN $28.40
- Resistance Level
- NBIX $128.66
- SNN $30.69
- Average True Range (ATR)
- NBIX 2.62
- SNN 0.39
- MACD
- NBIX -0.36
- SNN 0.06
- Stochastic Oscillator
- NBIX 84.17
- SNN 82.53
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.